SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
SECURITIES AND EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 7, 2003
GERON CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 0-20859 75-2287752
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification Number)
230 Constitution Drive 94025
Menlo Park, California (Zip Code)
(Address of principal executive offices)
(650) 473-7700
(Registrant's telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
On April 7, 2003, Geron Corporation, a Delaware corporation (the "Company"),
announced that it will present the positive preliminary results from a Phase 1
clinical trial of telomerase immunotherapy for metastatic prostate cancer on a
webcast conference call on, April 7, 2003 at 9:00 am Pacific Daylight Time. The
data were originally to be presented at the American Association of Cancer
Research (AACR) annual meeting in Toronto, which was cancelled last week due to
the outbreak of SARS.
The Company's press release announcing the webcast conference call and the
preliminary results is filed as an exhibit to this Current Report on Form 8-K.
The summary description of the event is qualified in its entirety by reference
to the document filed as an exhibit hereto.
Item 7. Exhibits.
Exhibits
--------
99.1 Press Release dated April 7, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GERON CORPORATION
Date: April 7, 2003 By:/s/ William D. Stempel
------------------------
Name: William D. Stempel
Title: Vice President and General Counsel
EXHIBIT INDEX
Exhibits
--------
99.1 Press Release dated January 21, 2003